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Methods

Case report
The female patient M. H. was the product of a full-term normal pregnancy and weighed 7 pounds at birth. Several severe episodes of bronchitis occurred before 5 years of age. The patient was hospitalized for an influenza-like syndrome when she was 5 years old; the mother (29 years) and one sibling (11 months) died from "influenza" at this time. From 5 to 10 years of age the patient was absent from school about one-third of the time because of infections of the upper respiratory tract. She was hospitalized at age 9 for severe upper respiratory infection, high fever, and unconsciousness. Intravenous glucose therapy promptly restored consciousness, and hypoglycemia was diagnosed but not documented. A similar episode and response to glucose therapy occurred a year later. A tonsillectomy was performed; continued postoperative nausea and vomiting necessitated hospitalization for 1 week.
By 16 years of age the patient was 5 feet 3 inches tall and had not menstruated. Disabling infections of the upper respiratory tract were frequent throughout her adult life. At age 17, the basal metabolic rate and the glucose tolerance test were within normal limits, and a roentgenogram of the skull showed no abnormalities. The patient had grown 4 inches, but menses had not commenced nor had secondary sex characteristics developed. An attempt to effect menses and development of secondary sex characteristics with hormones was made; the breasts developed slightly but menstruation did not occur. All studies were performed in the Clinical Study Center at San Francisco General Hospital periodically over a 2-year period. The patient was put on a constant metabolic diet, which contained 10 mEq Na and 74 mEq K per day by diet analysis. In some studies 6 g NaCl was added to increase Na intake to 122 mEq per day.
All basal steriod measurements were performed while the patient was on 122 mEq Na intake. The administration of corticotropin intramuscularly, 40 U every 12 hours for 5 days, and of angiotensin was also performed on this sodium intake. Pituitary suppression was achieved by administration of dexamethasone and cortisol. Levels of Na and K were measured in the urine daily and in the serum frequently by internal standard flame photometry. Serum chloride was measured by the Cotlove titrimeter technique (7) and serum CO2 by titrimetric and Van Slyke analysis (8) . The Na, K, and N contents were measured after acid digestion of samples of diet and stool.
Steroid measurements
Plasma. Cortisol and corticosterone were measured by a double isotope dilution derivative technique (9) . The half-life of corticosterone was determined after the intravenous administration of corticosterone-4-14C (10) . Aldosterone was measured by the constant infusion (daldosterone-1-2-3H) technique of Tait, Tait, Little, and Laumas (11). Progesterone was measured by the double isotope derivative technique (12) .2 Testosterone ( 13) and androstenedione (14) were determined by the double isotope derivative technique. 3 Secretion. The methods used to measure secretory rates of cortisol, corticosterone, and aldosterone have been reported previously (15) . Cortisol and corticosterone were determined by the double isotope dilution technique and aldosterone by the double isotope derivative technique.
The secretory rate of deoxycorticosterone (DOC) was determined as follows: A 3-uc dose of DOC-1-2-3H was administered intravenously, and urine was collected 24 Urine. The urine was assayed for follicle-stimulating hormone with the Steelman-Pohley technique (25) .
Miscellaneous measurements
Angiotensin sensitivity. The amount of angiotensin II amide required to raise diastolic and systolic blood pressures 20 mm Hg was determined by a technique similar to that of Kaplan and Silah (26) .
Insulin sensitivity. Insulin sensitivity was assessed after intravenous administration of .05 kg crystalline insulin 16 hours after fasting by measuring blood sugar (27) and levels of free fatty acids and glycerol in plasma. 10 Results C-21 steroids derived from progesterone. The concentration of progesterone in plasma was 0. 21 Mug per 100 ml (normal is 0.11 to 1.04), and that of pregnanediol in urine ranged from 2 to 11 mg per 24 hours (normal is 2 to 5) in three consecutive 24-hour collections. Urinary THDOC was 500 Mug per 24 hours (normal is 7 to 25), and secretion of DOC was 4.0 mg per 24 hours (normal is 0.050 to 0.160). The concentration of corticosterone in plasma ranged from 21 to 31 jug per 100 ml (normal is < 1) and showed a diurnal rhythm (25 at 8 a.m. and 9.1 Mfg per 100 ml plasma at 6 p.m.). The secretory rate of corticosterone was 112 to 124 mg per 24 hours (normal is 0.9 to 4.4). The TH-18-OH compound A in urine was 675 ug per 24 hours (normal is < 5 x TH aldosterone). No aldosterone was detected in plasma (normal is < 0.01 Mug per 100 ml plasma change in the secretory rates of corticosterone and aldosterone. The control rates of secretion of corticosterone and aldosterone were 112 mg and 10 ,ug per 24 hours, respectively. Effect of pituitary suppression on Na, K, and aldosterone excretion, serum K, and body weight during 122 mEq Na intake ( Figure 2 ). Administration of dexamethasone, 0.5 mg every 12 hours, for 6 days effected prompt Na diuresis, decrease in urinary K, increase in serum K from 2.9 to 4.5 mEq per L, and loss of weight. Cumulative Na excretion was 372 mEq and cumulative K retention, based on measurements made in urine, was 242 mEq per L. There was no change in aldosterone excretion; values were < 1 ,ug per 24 hours.
Effect of restricted Na intake and pituitary suppression on electrolyte balance, steroids, and body weight (Figure 3) . A 4-day control study after equilibration on 122 mEq Na intake was carried out. Potassium balance was slightly negative, and serum K levels were low. Corticosterone secretion was 124 mg per 24 hours, and plasma level was 20 pg per 100 ml. Aldosterone excretion was 1 jug per 24 hours, and secretion on day 1 was 10 ug per 24 hours. On day 4, THDOC was 500 ,g per 24 hours.
At the end of the control period added NaCl was removed from the diet. Renal sodium conservation on the sodium-limited diet was accomplished in the first 2 days of the 9-day study (even though a mild gastroenteric disorder and fever produced a brief negative Na and K balance on day 6. Potassium was retained, and serum K increased slightly. Aldosterone excretion remained at 1 pg per 24 hours, and after 9 days THDOC the level of serum K increased to 4.5 mEq per L and remained there. Blood pressure again returned to the normal range. Stilbestrol, 1 mg per day, was administered for 4 weeks; all measurements remained the same except the level of serum corticosterone, which was three times higher than that observed during administration of dexamethasone by itself. When cortisol and stilbestrol were discontinued, the level of corticosterone in plasma promptly rose to 25 pg per 100 ml. During the course of treatment upper respiratory infections and oral mucosal sores did not develop and stamina increased. Discussion A marked deficiency of adrenal 17a-hydroxylase activity is indicated by the absence of C-21 steroids derived from 17a-OH-progesterone and the minimal amounts of C-19 steroids derived from 17a-OH-progesterone and 17a-OH-pregnenolone. Furthermore, the negligible estrogen production, manifested clinically by the absence of secondary sex characteristics, the lack of estrinization, and the negligible amount of estrogens in urine, indicates additional evidence of diminished 17-hydroxylation in the ovary. The only steroids detected were those not dependent on this enzymatic process, namely, progesterone, DOC, corticosterone (B), and TH-18-OH compound A. Secretory rates of these steroids were greater than normal, permitting survival of the patient. The minimal amount of aldosterone secreted in the presence of increased secretion of B and excretion of TH-18-OH compound A may also indicate a second biosynthetic defect either in the conversion of 18-OH-B to aldosterone because of lack of dehydrogenase activity or in the conversion of angular methyl group of B to an aldehyde. The secretory rates of B and DOC were far greater than rates observed after infusion of ACTH (10) . Plasma levels of B were continually elevated and varied diurnally, and the pool size was much greater than normal. Metabolism of B was normal, indicated by the normal halflife. Corticosterone is not generally considered a mineralocorticoid, but the amounts secreted in this patient readily explain the presence of hypokalemic alkalosis, hypertension, and eosinophilia. Conn, Fajaris, and Louis demonstrated that similar amounts produce Na retention, K loss, and serum K reduction (28) . Corticosterone does not affect the circulatory eosinophil count or the excretion of ketosteroids and cortisol metabolites. Shortterm administration of B has no apparent effect on blood pressure, but continued and excessive secretion of this mineralocorticoid would be expected to cause hypertension eventually. The increased production of DOC also contributed to hypertension and hypokalemia. Mineralocorticoids have little, if any, effect on release of ACTH, as previously suggested, by failure to alter the urinary metabolites of cortisol (28) . However, because such large amounts of B are secreted there appears to be some control exerted on ACTH secretion in the absence of cortisol. Pigmentation did not increase in this patient. Plasma ACTH was slightly above the normal range and fluctuated diurnally. The adrenal glands were already responding maximally to endogenous ACTH judged by the lack of increase in secretion of corticosterone after 5 days of exogenous ACTH administration. The levels of ACTH observed, including the persistent diurnal pattern, are quite similar to those in patients with congenital adrenal hyperplasia (29) .
The levels of corticosterone secretion might be expected to affect carbohydrates and protein metabolites. However, growth was normal throughout life. Negative N balance was not detected during a 1-month study. Administration of B prevents hypoglycemia after fasting in patients with Addison's disease and decreases carbohydrate tolerance in normal subjects (28) . The blood glucose levels after fasting, the oral glucose tolerance test, and the insulin sensitivity test were normal in this patient. Thus, some glucocorticoid activity could be ascribed to the large quantities of corticosterone secreted. The frequency and severity of upper respiratory infections and the persistence of oral sores can be attributed to lack of cortisol and to minimal glucocorticoid activity of corticosterone. This is supported by the symptomatic improvement after dexamethasone and cortisol therapy. Levels of free fatty acids and glycerol in plasma were elevated in the presence of normal carbohydrate tolerance. The reason for this abnormality is not clear. It is unlikely that increased production of ACTH is responsible because ACTH levels were not particularly elevated. Lack of cortisol, normal amounts of growth hormone, and greater than normal amounts of B may be factors involved in this observation. Because B and DOC have little or no effect on release of ACTH and because circulating cortisol is absent, minimal inhibition of ACTH secretion could be a major factor in this disorder. Evidence for ACTH as the cause of the increased secretion of B and DOC, the hypertension, and the hypokalemia was effectively demonstrated by the correction of these abnormalities during slight pituitary suppression with dexamethasone and cortisol. Treatment with dexamethasone for 12 weeks effected the same response, but it was apparent that no mineralocorticoid activity was present, since serum K increased, salt craving occurred, and aldosterone was absent in the urine. These responses did not occur with comparable doses of cortisol for the same period of time, although blood pressure and plasma corticosterone levels were essentially the same. During the 4 weeks in which stilbestrol was administered in addition to cortisol all measurements remained the same except plasma corticosterone levels. The increase in B in plasma from 0.8 to 3 ,ug per 100 ml might be attributed to the effect of estrogens on steroid-binding globulin (30) .
A second biosynthetic defect may also be present. The diminished secretion and excretion of aldosterone remained essentially unchanged during the continued administration of ACTH and the 9 days of Na restriction and after the marked natriuresis that occurred with dexamethasone therapy. The negligible aldosterone secretion and excretion in this patient are similar to those observed after unilateral adrenalectomy for an aldosterone-producing tumor (31) . In these patients the reduced aldosterone secretion is a consequence of prolonged suppression of renin secretion (32) . The absence of plasma renin in this patient most likely results from excessive secretion of DOC and B, but whether or not this explains the lack of aldosterone secretion is not known at this time (33) . Before a second biosynthetic defect can be implicated, measurement of aldosterone secretion during more prolonged suppression of ACTH production is necessary. Precedence for such an abnormality can be found in patients with an aldosterone biosynthetic defect, with Na loss, with extensively increased secretion of 18-OH-B, and with slight increases in B secretion. Treatment with DOC and a high Na diet reduce the secretory rates of 18-OH-B and corticosterone in these patients (34) .
Whether or not "escape" from salt-retaining hormones occurred in this patient is not clear. Hypervolemia was not present. Excessive Na retention and K depletion were demonstrated by the diuresis of Na and retention of K during suppression of DOC and B and by the extremely low total body K. However, escape may not have occurred because administration of DOC acetate for 3 days produced further retention of Na and slight decrease in serum K.
Metyrapone, an 11,1-OH inhibitor, reduced the concentration of corticosterone in plasma by 50% and increased DOC production but had little effect on urinary electrolytes. The amount of corticosterone present during these two periods may have modified the Na response to exogenous and endogenous DOCG 17-Hydroxylation of steroids occurs only in the adrenal glands and the gonads. The absence of secondary sex characteristics and the negligible excretion of estrogens strongly suggest that the demonstrated 17-hydroxylase deficiency in the adrenal glands also occurs in the ovaries. In addition, the level of follicle-stimulating hormone was pathologically increased in this estrogen-deficient patient. The presence of a similar enzymatic defect in both the ovary and the adrenal gland suggests that the enzyme may be determined by a single gene. We do not know whether a similar defect was present in the sibling who died at 11 months of age or whether a partial defect was present in the mother. Summary A patient with deficiency of 17-hydroxylation activity in the adrenal glands is reported. A similar defect in the ovary is suggested. Corticosterone and deoxycorticosterone in excess produce a mineralocorticoid excess syndrome characterized by hypertension and hypokalemic alkalosis. The virtual absence of aldosterone secretion may represent a second biosynthetic defect. The importance of 17-hydroxylation in steroid biosynthesis is demonstrated in vivo. Amenorrhea, hypertension, and hypokalemic alkalosis are the indicators of a 17-hydroxylation deficiency.
